文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

血小板输注与合并血小板减少的消化道出血危重患者死亡率:一项回顾性队列研究

Platelet transfusion and mortality in critically ill patients with gastrointestinal bleeding and thrombocytopenia: A retrospective cohort study.
PubMed 文献 · Am J Emerg Med · 2025-09-19
一句话结论在合并血小板减少的消化道出血危重患者中,血小板输注与短期死亡率升高相关(HR 1.56),而与长期死亡率无关,作者建议对该人群谨慎输注血小板。

该回顾性队列研究利用MIMIC-IV数据库,纳入1275例合并血小板减少(血小板计数<150×10⁹/L)的消化道出血危重患者,分为血小板输注组和非输注组,采用Cox回归、Kaplan-Meier分析和倾向性评分匹配(PSM)评估血小板输注与28天(短期)及1年(长期)死亡率的关系。结果显示,血小板输注与短期死亡率升高显著相关(HR 1.56;95%CI 1.06-2.30),而与长期死亡率无关(HR 1.15;95%CI 0.89-1.50);PSM匹配195对后结果一致(短期HR 1.74;95%CI 1.08-2.79;长期HR 1.19;95%CI 0.86-1.64)。敏感性分析(包括残余混杂调整、IPTW及以14天和90天死亡率替代短期和长期死亡率)结果稳定。作者认为,尽管存在潜在残余混杂,该研究提示对该人群输注血小板应采取谨慎态度,并需在更大规模的前瞻性研究中验证。

要点

  • 在合并血小板减少(血小板计数<150×10⁹/L)的消化道出血危重患者中,血小板输注与28天死亡率升高独立相关(HR 1.56;95%CI 1.06-2.30)。
  • 倾向性评分匹配195对后,血小板输注与短期死亡率的相关性保持一致(HR 1.74;95%CI 1.08-2.79)。
  • 血小板输注与1年长期死亡率无关(全队列HR 1.15;95%CI 0.89-1.50;PSM后HR 1.19;95%CI 0.86-1.64)。
  • 敏感性分析(残余混杂调整、IPTW、以14天和90天死亡率替代短期和长期死亡率)结果稳定。
  • 作者认为,尽管存在潜在残余混杂,该研究提示对合并血小板减少的消化道出血危重患者输注血小板应采取谨慎态度。

适用人群与场景

  • 合并消化道出血且血小板计数<150×10⁹/L的危重患者,数据来源于MIMIC-IV数据库。

诊断标准与关键阈值

  • 消化道出血合并血小板计数<150×10⁹/L。

研究设计与关键结果

  • 研究类型为回顾性队列研究,利用MIMIC-IV数据库,共纳入1275例合并血小板减少的消化道出血危重患者,分为血小板输注组和非输注组。
  • 扩展Cox比例风险回归分析显示,血小板输注与短期死亡率升高显著相关(HR 1.56;95%CI 1.06-2.30),与长期死亡率无显著关联(HR 1.15;95%CI 0.89-1.50)。
  • 倾向性评分匹配成功匹配195对,匹配后血小板输注与短期死亡率仍显著相关(HR 1.74;95%CI 1.08-2.79),与长期死亡率无关(HR 1.19;95%CI 0.86-1.64)。
  • 敏感性分析(包括残余混杂调整、IPTW、以14天和90天死亡率分别替代短期和长期死亡率)结果稳定。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:作为观察性研究,尽管进行了严格的匹配和敏感性分析,仍可能存在残余混杂。
  • 作者指出这些发现需在更大规模的前瞻性研究中验证。

对床旁实践的改变

  • 作者认为,对于合并血小板减少的消化道出血危重患者,血小板输注与短期死亡率升高相关,提示应采取谨慎的输血策略。
  • 该研究未提供血小板输注的剂量、阈值或具体方案,临床决策需结合个体情况。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: It is unclear what role platelet transfusion plays in thrombocytopenic patients with gastrointestinal bleeding (GIB). The study explored the effects of platelet transfusion on clinical outcomes in thrombocytopenic GIB patients who were critically ill.

METHODS: Using the MIMIC-IV database, we conducted a retrospective cohort study in which patients with GIB and a platelet count <150 × 109/L were identified and stratified into platelet transfusion and non-transfusion groups. Cox regression models, Kaplan-Meier analysis, and propensity score matching (PSM) were applied to study the association between platelet transfusion and mortality over both 28-day (short-term) and 1-year (long-term) periods.

RESULTS: The study included 1275 patients in total. Extended Cox proportional hazards regression analysis demonstrated a significant association between platelet transfusion and increased short-term mortality (HR 1.56; 95 % CI 1.06-2.30), whereas no such association was found for long-term mortality (HR 1.15; 95 % CI 0.89-1.50). PSM resulted in 195 cases being successfully matched in each group. A significant relationship was consistently found between platelet transfusion and short-term mortality (HR 1.74; 95 % CI 1.08-2.79), but not with long-term mortality (HR 1.19; 95 % CI 0.86-1.64). The association was stable in the sensitivity analyses, including residual confounding adjustment, IPTW, and using 14-day and 90-day mortality as surrogates for short-term and long-term mortality, respectively. However, as with any observational study, residual confounding may persist despite rigorous matching and sensitivity analyses.

CONCLUSIONS: Despite potential residual confounding, this retrospective cohort study of critically ill patients with thrombocytopenic GIB found that platelet transfusion was associated with higher short-term mortality but did not affect long-term mortality. These findings suggest a cautious approach to platelet transfusion in this population, though they should be validated in larger prospective investigations.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Wang L, Xu X, Li R, et al. Platelet transfusion and mortality in critically ill patients with gastrointestinal bleeding and thrombocytopenia: A retrospective cohort study. Am J Emerg Med. 2025. PMID: 41004926. doi:10.1016/j.ajem.2025.09.035

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。